Press Release — For Immediate Release

RainDance Extends Sequence Enrichment Solution Capabilities With Methyl-Seq

and Ultra-Deep Resequencing Applications

HONOLULU, HAWAII, U.S.A., October 22, 2009 — RainDance Technologies, Inc., a

leading provider of innovative microdroplet-based solutions for human health and disease
research, announced today it will extend the capabilities of its Sequence Enrichment
Solution by offering Methyl-Seq and Ultra-Deep Resequencing applications.

In a presentation at the 59th Annual Meeting of the American Society of Human Genetics,
the company said these enhancements represent a significant expansion of the RainDance
technology platform’s capabilities. They will enable researchers to use their RDT 1000
instruments for epigenomic and ultra-deep resequencing studies that can accurately
characterize the molecular basis for cancer and other destructive diseases.

“Methyl-Seq and Ultra-Deep Resequencing will provide exciting new tools to our customers’
research methodologies,” said Christopher McNary, President and Chief Executive Officer,
RainDance Technologies. “Now scientists can apply our Sequence Enrichment Solution to
gain better understanding of how disease cells differ from normal cells, enhancing their
understanding of the origins and pathways of complex diseases.”

Methyl-Seq Allows Use of PCR-Based Enrichment and Next-Generation Sequencing

for Higher-Resolution Epigenomic Studies

RainDance said its Methyl-Seq application will provide scientists with new capabilities for
epigenomics research, a field recognized in a National Institutes of Health Roadmap as
having exceptionally high potential to transform biomedical research. The study of
epigenomics explores how factors such as environment can change gene expression and
gene activity over time in a manner that heightens susceptibility to disease.

The Methyl-Seq application will allow researchers, for the first time, to combine PCR-based
sequence enrichment with the power of next-generation sequencing platforms to perform
epigenomic studies at significantly higher resolution. By studying methylation patterns with
single-base resolution across targeted regions of the genome, researchers can get a better
understanding of epigenomic variation and can discover opportunities to develop new
treatments for cancer and other complex diseases.

“Methyl-Seq enables the targeted amplification and next-generation sequencing of bisulfite-

converted DNA for the identification of methylated bases in the genome with greater
accuracy and quality of data,” said McNary.

Ultra-Deep Resequencing Enables PCR-Based Enrichment to Accurately

Characterize Variance in Heterogeneous Samples
RainDance’s Ultra-Deep Resequencing application enables the use of the company’s PCR-
based Sequence Enrichment Solution to accurately characterize rare variants in highly
heterogeneous samples, such as those found in cancer tumors. Studies suggest that rare
genetic variants may play significant roles in tumorigenesis, pathogenesis, and disease
progression. Previously, ultra-deep resequencing of heterogeneous samples with standard
PCR approaches has been difficult because of the loss of accurate DNA representation.

“The unique compartmentalization capability of our RainStorm microdroplet-based

technology provides highly efficient amplification of all sequence variants in the sample,”
McNary said. “This ensures that accurate representation and a high depth of coverage are
maintained for ultra-low frequency variants.”

Both the Methyl-Seq and Ultra-Deep Resequencing applications will be commercially

available during the first half of 2010. They will utilize the RDT 1000 system’s proven
consumables and reagents.

“The capabilities of these new applications, plus the expanded-content DNA primer libraries
and WGA sample protocols announced last month, make the RDT 1000 a highly flexible
genomic research platform that easily integrates with any next-generation sequencing
workflow,” said McNary. “Both the Methyl-Seq and Ultra-Deep Resequencing applications
are simple to use and integrate seamlessly with our Sequence Enrichment Solution. Our
applications will help researchers rethink their approaches to discovery as they unlock the
cures for the world’s most devastating diseases,” he said.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for
single-cell analyses that will accelerate human health and disease research. The speed and
simplicity of the company’s exciting new technology platform enable researchers to design
experiments in ways that were previously unaffordable or unimaginable. The company’s
RainStormTM technology produces picoliter-volume droplets at a rate of 10 million per hour.
Each droplet is the functional equivalent of an individual test tube and can contain a single
molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed
workflows with minimized process-induced bias or error.

RainDance’s initial application focuses on the targeted sequencing of the human genome —
one of the fastest-growing segments of the $1 billion DNA sequencing market. This
application enables the high-resolution analysis of genetic variation between individuals and
populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

Contact RainDance Technologies

• Press inquiries: Don Goncalves, 781-793-9380, dgoncalves@tizinc.com
• Corporate questions: Steve Becker, 781-861-6300, beckers@raindancetech.com
• Technical questions: Jim Brayer, 781-861-6300, brayerj@raindancetech.com
• In Europe: Patrick Kelly, +44-786-3200-242, kellyp@raindancetech.com